Impact of rheumatoid arthritis in Turkey: a questionnaire study

Basit Öğe Kaydı
dc.authorid0000-0002-3273-7969en_US
dc.authorid0000-0003-2598-5806en_US
dc.authorid0000-0002-3718-171Xen_US
dc.contributor.authorDireşkeneli, Haner
dc.contributor.authorAkkoç, Nurullah
dc.contributor.authorBes, Cemal
dc.contributor.authorÇakır, Necati
dc.contributor.authorÇefle, Ayşe
dc.date.accessioned2021-06-23T19:35:45Z
dc.date.available2021-06-23T19:35:45Z
dc.date.issued2014
dc.departmentBAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractObjective Unmet needs of rheumatoid arthritis (RA) patients regarding physician/patient communication, treatment preferences and quality of life issues were investigated in a Turkish survey study. Methods The study was conducted with the contribution of 33 rheumatologists, and included 519 RA patients. The study population included patients who had been on biologic therapy for >6 months and were still receiving biologic therapy (BT group), and those who were biologic naive, but found eligible for biologic treatment (NBT group). Of the RA patients, 35.5% initially had a visit to an internal disease specialist, 25.5% to a physical therapy and rehabilitation specialist, and 12.2% to a rheumatology specialist for their RA complaints. The diagnosis of RA was made by a rheumatologist in 48.2% of patients. Results The majority of RA patients (86.3%) visit their doctor within 15-week intervals. Most of the physician-patient communication focused on disease symptoms (99.0%) and impact of the disease on quality of life (61.8%). The proportion of RA patients who perceived their health status as good/very good/excellent was higher in the BT group than in the NBT group (74.3% vs. 51.5%, p<0.001). However, of those RA patients in the NBT group, only 24.8% have been recommended to start a biologic treatment by their doctors. With respect to dose frequency options, once-monthly injections were preferred (80%) to a bi-weekly injection schedule (8%). Conclusion In conclusion, RA patients receiving biologic therapy reported higher rates of improved symptoms and better quality of life and seemed to be more satisfied with their treatment in our study.en_US
dc.identifier.endpage483en_US
dc.identifier.issn0392-856X
dc.identifier.issue4en_US
dc.identifier.pmid24960289en_US
dc.identifier.startpage477en_US
dc.identifier.urihttps://www.clinexprheumatol.org/abstract.asp?a=7478
dc.identifier.urihttps://hdl.handle.net/20.500.12491/7860
dc.identifier.volume32en_US
dc.identifier.wosWOS:000341171000006en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorBes, Cemal
dc.language.isoenen_US
dc.publisherClinical & Exper Rheumatologyen_US
dc.relation.ispartofClinical And Experimental Rheumatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectRheumatoid Arthritisen_US
dc.subjectQuality of Lifeen_US
dc.subjectPatient Surveyen_US
dc.titleImpact of rheumatoid arthritis in Turkey: a questionnaire studyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
haner-direskeneli.pdf
Boyut:
354.73 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam metin/Full text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu